News

The Phase II trial (BGBC007) follows a two-stage design: it is an open label, multi-centre study of bemcentinib in combination with KEYTRUDA in patients with previously treated, locally

As a result of the Acquisition, DanDrit owns a perpetual, fully paid up, royalty free, sublicensable, exclusive, license to new technology platforms for the treatment of HIV, including

The improvement was seen 12 weeks after treatment with Taltz injection, in comparison to placebo, said Lilly. The company said that 92% of patients treated with Taltz had

Cosentyx is a fully human interleukin-17A (IL-17A) inhibitor, which showed speedy and sustained long term efficacy in treating patients with moderate-to-severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondilytis

As announced in a press release dated November 7, 2017, a previous U.S Phase III study did not meet its primary endpoint – change in worst leg pain

QVAR® RediHaler™ is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and

The approval is for the expanded use of Imfinzi to treat NSCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). Imfinzi, which

The funding has been allotted to spend over five years across eight CTUs in Cardiff, Birmingham, Glasgow, Southampton, Leeds and London. The CTUs are engaged in the designing, delivery

NF1 is an incurable genetic condition that affects one in 3,000 births, with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and orthopaedic (skeletal) manifestations. NF1 can cause